Research Topics
Genomes and Genes | Gerald BatistSummaryAffiliation: McGill University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapyGerald Batist
Jewish General Hospital, McGill University, 3755 Cote St Catherine, Montreal, PQ, H3T 1E2 Canada
Expert Opin Pharmacother 3:1739-51. 2002..The development of Myocet, a less cardiotoxic, better tolerated and equally efficacious doxorubicin, extends the therapeutic options in the overall management of breast cancer...- Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: resuGerald Batist
Jewish General Hospital, McGill University Department of Oncology, Montreal, Quebec, Canada, Duke University Medical Center, Durham, North Carolina, USA
Anticancer Drugs 17:587-95. 2006..This analysis revisits the therapeutic option of including doxorubicin in the treatment of MBC patients who have had prior adjuvant anthracycline exposure... - Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancerG Batist
Jewish General Hospital, McGill University, Montreal, Quebec, Canada
J Clin Oncol 19:1444-54. 2001.... - Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levelsG Batist
McGill Center for Translational Research in Cancer, McGill University, Montreal, Quebec, Canada
Ann Oncol 13:1259-63. 2002..Neovastat (60 or 240 ml/day) was administered orally (b.i.d.) to 144 patients with solid tumors refractory to standard therapies or for whom no standard treatments were available... 
Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapyMartin Loignon
Segal Cancer Centre, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
Mol Cancer Ther 8:2432-40. 2009..This high Cul3/low Nrf2 signature may be key to cellular sensitivity to both chemical carcinogeneic stimuli as well as to cytotoxicity of commonly used chemotherapeutic drugs in established breast cancers...- Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cellsAla Eddin Al Moustafa
Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
Oncogene 23:5252-6. 2004..Our data suggest that anti-cyclin D1 therapy may be highly specific in the treatment of all human cancers expressing high-risk HPVs or HPVs/ErbB-2... - Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort studyMartine T E Puts
McGill University Université de Montréal Solidage Research Group on Frailty and Aging, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Drugs Aging 27:559-72. 2010..Older cancer patients are possibly at an increased risk of medication-related problems because, typically, they receive many medications during their cancer treatment, both for the cancer itself and for supportive care... - Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapiesLiangao Hu
Department of Oncology, Segal Cancer Centre, Lady Davis Institute for Medical Research, Center for Experimental Therapeutics in Cancer, Sir Mortimer B Davis Jewish General Hospital, McGill University, 3755 Cote Sainte Catherine Road, Montreal, QC, H3T 1E2, Canada
Cancer Chemother Pharmacol 66:467-74. 2010.... - Connexin43 pseudogene in breast cancer cells offers a novel therapeutic targetAndrew Bier
Department of Oncology, Segal Cancer Centre, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, and Department of Biochemistry and McGill Cancer Centre, McGill University, Montreal, Quebec, Canada H3T 1E2
Mol Cancer Ther 8:786-93. 2009..Our results show that PsiCx43 acts as a posttranscriptional regulator of Cx43 in breast cancer cells, and that this represents an example of the regulation of genes by pseudogenes with potential therapeutic implications in cancer... - Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot studyMartine T E Puts
Solidage Research Group on Frailty and Aging, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
Crit Rev Oncol Hematol 78:138-49. 2011..The concept of frailty may be useful to characterize vulnerability. The aim of this pilot study was to explore the association between frailty/functional status and treatment toxicity at 3 months and mortality at 6 months... - Characteristics of older newly diagnosed cancer patients refusing cancer treatmentsMartine T E Puts
McGill University Université de Montréal Solidage Research Group on Frailty and Aging, Montreal, QC, Canada
Support Care Cancer 18:969-74. 2010..The aim of this paper was to describe the health and functional status characteristics of patients who refused cancer treatment... - A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cellsMaite Hernandez
Departments of Medicine, Oncology, and Pharmacology and Therapeutics, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, 3755 Chemin de la Cote Ste-Catherine, Montreal, Quebec, Canada
Prostate 66:1151-61. 2006..TSA increased the level of hyperacetylated histones bound to cx43 promoter. CONCLUSION: Our results highlight the potential utility of inhibitors of HDAC to restore cx43 gene expression in prostate cancer... - Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitorsVictor Cohen
Segal Cancer Center, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Cancer 116:4309-17. 2010..Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKI) in patients with nonsmall cell lung cancer (NSCLC)... - Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymesWeimin Miao
Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis Jewish General Hospital and Department of Oncology, McGill University, Montreal, Quebec H3T 1E2, Canada
J Biol Chem 280:20340-8. 2005..Moreover, direct regulation of NRF2 by AHR contributes to couple phase I and II enzymes into an integrated system facilitating more effective xenobiotic and carcinogen detoxification... - Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinomaLyndsay Harris
Duke University Medical Center, Durham, North Carolina, USA
Cancer 94:25-36. 2002.... - Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physiciansDoreen Wan-Chow-Wah
Division of Geriatric Medicine, Jewish General Hospital, Montreal, Quebec, Canada
Crit Rev Oncol Hematol 78:45-58. 2011..The management of older cancer patients is often suboptimal. This study aims to understand the management of older cancer patients who may receive chemotherapy... - Medication problems in older, newly diagnosed cancer patients in Canada: How common are they? A prospective pilot studyMartine T E Puts
Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Drugs Aging 26:519-36. 2009..Few studies have examined the scope of this problem in older newly diagnosed cancer patients... - Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1Jian H Wu
Montreal Centre for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, QC, Canada
Chem Biol Drug Des 75:475-80. 2010..Further, BM31 and BM40 potently induce expression of ARE-regulated enzyme gamma-glutamylcysteine synthetase. We demonstrated that BM31 provides protections for the MCF-7 cells from cytotoxic damage of carcinogen benzo[a]pyrene... - A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulatorsWeimin Miao
Department of Oncology, Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, 3755 Cote-St-Catherine Road, Montreal, Quebec, Canada H3T 1E2
Biochem Pharmacol 67:1897-905. 2004..Finally, this cell-based system permitted us to identify a potential novel mechanism for cross-talk between the ARE and the xenobiotic response element (XRE)-mediated pathways... - Novel use of the fluorescent dye 5-(and-6)-chloromethyl SNARF-1 acetate for the measurement of intracellular glutathione in leukemic cells and primary lymphocytesDavid Hamilton
Department of Pharmacology and Therapeutics, The Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Cytometry A 71:709-15. 2007..80-0.88. CM-SNARF can be used to semi-quantitatively and rapidly determine intracellular variations in GSH concentration in the range of 10-150 nmoles GSH/mg protein... - Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitorsDavid Hamilton
Department of Oncology, McGill University, Montreal Centre for Experimental Therapeutics in Cancer and Segal Cancer Centre, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
Mol Pharmacol 71:1140-7. 2007..This work validates the use of model-based database mining and identified inhibitors of gamma-GCS(H) with novel chemical structures... - Syntheses and potential anti-prostate cancer activities of ionone-based chalconesJinming Zhou
Department of Oncology, McGill University, Montreal, Canada
Bioorg Med Chem Lett 19:1183-6. 2009.... - Connexin43 pseudogene is expressed in tumor cells and inhibits growthMustapha Kandouz
Department of Oncology, Montreal Centre for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada H3T 1E2
Oncogene 23:4763-70. 2004..Based on our findings, PsiCx43 joins and enlarges the thus far restricted group of functionally transcribed and translated pseudogenes... 
Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retentionMartine T E Puts
Solidage Research Group, Université de Montréal McGill University Research Group on Frailty and Aging, Montreal, Canada
BMC Cancer 9:277. 2009..This paper reports on strategies to recruit older newly-diagnosed cancer patients prior to treatment into an observational prospective pilot study and to retain them during a six-month period...- Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analoguesP James Scrivens
Lady Davis Institute for Medical Research, SMBD Jewish General Hospital, Montreal, Quebec, Canada
Mol Cancer Ther 2:1053-9. 2003.... - Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissuesBruce Gottlieb
Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
Hum Mutat 34:610-8. 2013.... - The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathwaysMustapha Kandouz
Montreal Centre for Experimental Therapeutics in Cancer, Segal Cancer Centre, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, QC, Canada
Cell Cycle 9:398-407. 2010..Finally, EphB2 expression inactivates Akt, which is a known inhibitor of autophagy. In conclusion, the EphB2 receptor induces an autophagic cell death that is mediated through the ERK1/2 and PI3K/Akt pathways... - Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsGerald Batist
Segal Cancer Center, Sir Mortimer B Davis Jewish General Hospital, Department of Oncology, McGill University, Montreal, Quebec, Canada
Clin Cancer Res 15:692-700. 2009..This open-label, single-arm, dose-escalating phase I study was designed to determine the maximum tolerated dose and pharmacokinetics of CPX-1 in patients with advanced solid tumors... - Clinical experience of cancer specialists and geriatricians involved in cancer care of older patients: A qualitative studyM T E Puts
Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
Crit Rev Oncol Hematol 74:87-96. 2010..Cancer is an important health problem in older persons. The aim of this study was to explore how cancer specialists and geriatricians manage the treatment of older patients with cancer... - E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cellsAla Eddin Al Moustafa
Lady Davis Institute for Medical Research of the Sir Mortimer B Davis Jewish General Hospital, Department of Medicine, and Center for Translational Research in Cancer, Quebec, Canada
Oncogene 23:350-8. 2004..This conversion leads to the upregulation of cyclin D1, c-myc and other oncoproteins necessary for alteration of the E-cadherin/catenin complex and cell transformation of NOE cells... - The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity actionKhadidja Haidara
Department of Oncology, Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, McGill University, Montreal, Que, Canada H3T 1E2
Cancer Lett 242:180-90. 2006..A number of features suggest that Casticin could be important in cancer therapy. Indeed, Pgp over expressing cells are not resistant to Casticin, and its cell killing effect is observed even in p53 mutant or null cell lines... - The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility studyCarmen G Loiselle
School of Nursing, Faculty of Medicine, McGill University, Montreal, Canada
Patient Educ Couns 80:48-55. 2010..To examine the impact of an 8-week cancer multimedia informational intervention on health-related outcomes among individuals newly diagnosed with cancer... - Cardiac safety of liposomal anthracyclinesGerald Batist
The Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, QC, Canada
Cardiovasc Toxicol 7:72-4. 2007..A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity... - Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancerVictor Cohen
Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
Cancer 107:2858-65. 2006..The use of denaturing high-performance liquid chromatography (dHPLC) as a method to screen for the 2 predominant EGFR mutations is reported... - The biology of melanoma prognostic factorsAlan Spatz
Department of Pathology, Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Discov Med 10:87-93. 2010..This will lead to the development of platforms which can be used by scientists from different fields to integrate and share high-quality data in the pre-competitive setting and generate new probabilistic causal models... - Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive elementWeimin Miao
Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis-Jewish General Hospital, 3755 Cote Sainte Catherine Road, Montreal, Quebec, Canada H3T 1E2
Mol Pharmacol 64:346-54. 2003..Oltipraz is a bifunctional inducer, modulating both phase I and II drug-metabolizing enzymes to enhance carcinogen detoxification... - TLK-199 (Telik)David Hamilton
Sir Mortimer B Davis-Jewish General Hospital, Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada
IDrugs 8:662-9. 2005..Telik Inc is developing TLK-199, an intravenous inhibitor of glutathione S-transferase P1-1, for the potential prevention of myelosuppression in blood diseases, namely myelodysplastic syndrome... - Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot studyFrederique Retornaz
Division of Geriatric Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
J Gerontol A Biol Sci Med Sci 63:518-22. 2008..Choosing the most sensitive tools to assess their health status is a major issue. This cross-sectional study explores the usefulness of frailty markers in detecting vulnerability in older cancer patients... - Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cellsAla-Eddin Al Moustafa
Lady Davis Institute for Medical Research of the Sir Mortimer B Davis-Jewish General Hospital, Department of Medicine, McGill Center for Translational Research in Cancer, 3755, Ch. de la Cote Ste-Catherine, Montreal, Quebec, Canada H3T 1E2
Oncogene 21:2634-40. 2002..These findings provide a large body of information regarding gene expression profiles associated with head and neck carcinogenesis, and also represent a source of potential targets for HNSCC prevention and/or therapeutics... - AE-941 (Neovastat): a novel multifunctional antiangiogenic compoundD Gingras
, , , 3175, , , , Canada
Expert Rev Anticancer Ther 1:341-7. 2001..Moreover, the median survival time in patients with renal cell carcinoma and non-small cell lung cancer was significantly longer in patients receiving high doses of AE-941 compared to low doses... - Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up careAnnett Körner
Department of Educational and Counselling Psychology, McGill University, 3700, rue McTavish, Montreal, QC, H3A 1Y2, Canada
BMC Dermatol 13:3. 2013..The main objective of the current project is to examine psychosocial predictors of skin self-examination using on a rigorous and clinically sound methodology... - Glutathione and glutathione analogues; Therapeutic potentialsJian Hui Wu
Segal Cancer Centre, Lady Davis Research Institute of the Jewish General Hospital, McGill University, Canada
Biochim Biophys Acta 1830:3350-3. 2013..Glutathione (GSH) and related enzymes are critical to cell protection from toxins, both endogenous and environmental, including a number of anti-cancer cytotoxic agents... - The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4Maha Katabi
McGill Center for Translational Research in Cancer, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
Mol Ther 5:170-6. 2002.... - The biology behind prognostic factors of cutaneous melanomaAlan Spatz
Segal Cancer Centre Jewish General Hospital, Departments of Pathology and Oncology, McGill University, Montreal, Canada
Curr Opin Oncol 22:163-8. 2010..This review focuses on recent biological data that shed light on the clinico-biological correlations that support the 2010 AJCC melanoma staging system... - An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypesYoussef A Elhaji
Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
Mol Endocrinol 18:1876-86. 2004..Such novel computational modeling may lead to a better understanding of the structure-function relationships and the molecular mechanics of ligand binding not only of the AR-LBD but also of other nuclear receptors... - Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapyVictor Cohen
Department of Medicine, McGill University, Montreal, Canada
Clin Cancer Res 9:1611-5. 2003..The aim of the present study was to investigate the association between the MTHFR polymorphism and response to 5-FU and other fluoropyrimidines in patients with metastatic colorectal cancer... - [The réseau de recherche sur le cancer: favoring a multi-disciplinary approach]Anne Marie Mes-Masson
Direction du réseau de recherche sur le cancer, Centre de recherche du Centre hospitalier de l Université de Montréal CHUM et Institut du cancer de Montréal, Montreal, Quebec, Canada
Bull Cancer 93:831-4. 2006..Optimization of resources is made possible by the contributions of basic scientists and clinicians working together towards a unified objective: fighting cancer... - Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cellsX Chen
McGill Center for Translational Research in Cancer, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
Biochem Pharmacol 56:743-9. 1998..These results indicate a critical interaction between cellular GSH levels and 5-OPase activity that could be important in GSH modulation in therapeutic settings... - The glutathione system in alkylator resistanceDavid Hamilton
Department of Pharmacology and Therapeutics, McGill University, Lady Davis Institute for Medical Research, Sir Mortimer B Davis-Jewish General Hospital, , , Canada
Cancer Treat Res 112:67-87. 2002 - A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione productionDavid Hamilton
Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada
Blood 102:725-30. 2003.... - Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumorsR Lapointe
, St-Luc Hospital, Montreal, Quebec, Canada
Ann Oncol 16:289-93. 2005..CONCLUSION: Troxacitabine administered by a bolus daily x5 monthly regimen has modest activity in advanced pancreatic adenocarcinoma... - Potential for selective modulation of glutathione in cancer chemotherapyX Chen
Department of Experimental Medicine, McGill University, Montreal, QC, Canada
Chem Biol Interact 111:263-75. 1998..Preliminary studies suggest that gap junction induction may dramatically deplete GSH concentration in tumor cells and sensitize them to a variety of treatments... - Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats: a potential new target for biochemical modulation of glutathioneX Chen
McGill Center for Translational Research in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Clin Cancer Res 4:131-8. 1998..In colon tissues, there is no significant difference in 5-OPase level between the normal and tumor tissues. These findings could have implications for both carcinogenesis and therapy... - New taxane analogues from the needles of Taxus canadensisJ Zhang
Human Health Research Center, INRS-Institut Armand-Frappier, , 531 Boulevard des Prairies, Laval, , Canada, H7V 1 B7
J Nat Prod 64:450-5. 2001..Four of these metabolites are new taxane analogues: 7-acetyl-10-deacetyltaxol (1), 2'-acetyl-7-epi-cephalomannine (2), 10-deacetyl-10-oxo-7-epi-cephalomannine (3), and 10-acetylglycollylbaccatin VI (4)... - A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cellsC Trudeau
Department of Pharmacology, , , , Canada
Hum Gene Ther 12:1673-80. 2001..Our study shows that this novel system may represent a therapeutic tool for gene prodrug targeting of lung cancer, considering the fact that allopurinol is well tolerated in humans... - The role of connexin-mediated cell-cell communication in breast cancer metastasisG D Carystinos
Department of Oncology, McGill University Centre for Translational Research in Cancer, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada
J Mammary Gland Biol Neoplasia 6:431-40. 2001..This is probably because of the loss of cooperation between neighboring cells, leading to cell heterogeneity and cell dissociation in the tumor. The possible involvement of Cx activity during metastasis will be discussed... - SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumorsL Panasci
McGill Center for Translational Research in Cancer, Jewish General Hospital, Montreal, Quebec, Canada
J Clin Oncol 21:232-40. 2003..The purpose of this phase I study was to determine the maximum-tolerated dose (MTD), the toxicity profile, the pharmacokinetics profile, and recommended phase II dose... - AnthracyclinesDavid Hamilton
Department of Pharmacology and Therapeutics, The Montreal Center for Experimental Therapeutics in Cancer, Sir Mortimer B Davis--Jewish General Hospital, , , Canada
Cancer Chemother Biol Response Modif 22:19-33. 2005 - Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerChristine E Swenson
Elan Pharmaceuticals, Inc, Princeton, NJ 08540, USA
Anticancer Drugs 14:239-46. 2003..There was a correlation between the plasma AUC(0-infinity) of total doxorubicin and the degree of myelosuppression in patients receiving conventional doxorubicin, but this correlation was not found in patients receiving TLC D-99... - A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patientsManijeh Daneshmand
Ottawa Regional Cancer Centre, Ottawa, Ontario, K1H 1C4 Canada
Clin Cancer Res 9:2457-64. 2003..ZD1839 may also induce cancer cell apoptosis in a subset of colorectal cancer patients via up-regulation of p27(Kip1)... - A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancerMary J Mackenzie
Hamilton Regional Cancer Centre, 699 Concession St, Hamilton, ON, Canada L8V 5C2
Invest New Drugs 23:165-70. 2005..There were no treatment related deaths. CONCLUSIONS: ZD1839, when given at 750 mg/day to patients with pre-treated metastatic colorectal cancer, does not result in significant tumor regression...